Ultragenyx Pharmaceutical Inc
RARE
Company Profile
Business description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Contact
60 Leveroni Court
NovatoCA94949
USAT: +1 415 483-8800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,294
Stocks News & Analysis
stocks
The trillion-dollar club: Are these mega-sized stocks still buys?
The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
stocks
New pricing model for embattled ASX tech leader
Investor day shows off potentially disruptive pricing model.
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
Shares trade at a discount despite attractive longer-term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,918.20 | 11.40 | 0.13% |
| CAC 40 | 8,128.27 | 40.85 | 0.51% |
| DAX 40 | 23,882.03 | 188.32 | 0.79% |
| Dow JONES (US) | 47,850.94 | 31.96 | -0.07% |
| FTSE 100 | 9,706.98 | 14.91 | 0.15% |
| HKSE | 25,818.34 | 117.56 | -0.45% |
| NASDAQ | 23,505.14 | 51.04 | 0.22% |
| Nikkei 225 | 50,275.20 | 753.22 | -1.48% |
| NZX 50 Index | 13,462.03 | 53.59 | -0.40% |
| S&P 500 | 6,857.12 | 7.40 | 0.11% |
| S&P/ASX 200 | 8,624.30 | 10.20 | 0.12% |
| SSE Composite Index | 3,869.29 | 6.50 | -0.17% |